期刊文献+

综合ICU医院获得性肺炎感染菌株及耐药性分析 被引量:4

Analysis of infected strains and bacterial resistance of hospital acquired pneumonia in general intensive care unit
原文传递
导出
摘要 目的分析医院综合重症监护病房(GICU)医院获得性肺炎(HAP)感染菌株特点及耐药情况。方法回顾性分析GICU收治61例HAP患者的感染菌株及其对抗菌药物耐药性。结果61例HAP患者中,共检出213株菌。革兰阴性杆菌99株(46.5%),以鲍曼不动杆菌、肺炎克雷伯菌、铜绿假单胞菌和大肠埃希菌为主;革兰阳性球菌81株(38.0%),以肠球菌、金黄色葡萄球菌、表皮葡萄球菌和溶血葡萄球菌为主;真菌33株(15.5%),以白色念珠菌和非白色念珠菌为主。鲍曼不动杆菌株较多对抗生素多重耐药,未发现耐万古霉素的肠球菌株和葡萄球菌株。结论应根据细菌病原学及抗菌药物耐药性,合理选择抗菌药物,控制GICU内HAP感染的发生,减少耐药菌的出现。 Objective To analyze the infected strains and bacterial resistance of hospital acquired pneumonia(HAP)in general intensive care unit(GICU).Methods Data of isolated infected strains and their resistance to anti-biotics in 61 patients with HAP in GICU were retrospectively analyzed.Result A total of 213 bacteria strains was isolated in 61 HAP patients,of which 99(46.5%)strains were gram-negative bacteria,81(38.0%)strains were gram-positive bacteria and 33(15.5%)strains were fungus.Gram-negative bacteria included mainly acinetobacter baumannii,klebsiella pneumoniae,pseudomonas aeruginosa and escherichia coli.Gram-positive bacteria included mainly enterococcus,staphylococcus aureus,epidermis staphylococcus and hemolytic staphylococci.Fungus included mainly candida albicans and non-candida albicans.Acinetobacter baumannii strains tended to have multiple drug resistance.No strain of staphylococcus and enterococcus resistant to vancomycin was found.Conclusion According to bacterial etiology characteristics and bacterial resistance,antibiotics should be reasonably selected to control HAP in GICU and reduce the occurence of drug-resistant bacteria.
作者 成云兰 朱滨
出处 《江苏医药》 CAS 2015年第6期677-679,共3页 Jiangsu Medical Journal
关键词 医院获得性肺炎 重症监护病房 Hospital acquired pneumonia Intensive care unit
  • 相关文献

参考文献4

二级参考文献14

  • 1陈翔敏,华占楼.68例老年肺部感染相关因素分析[J].江苏医药,2005,31(12):950-950. 被引量:2
  • 2刘又宁,陈民钧,赵铁梅,王辉,王睿,刘庆锋,蔡柏蔷,曹彬,孙铁英,胡云建,修清玉,周新,丁星,杨岚,卓建生,唐英春,张扣兴,梁德荣,吕晓菊,李胜歧,刘勇,俞云松,魏泽庆,应可净,赵峰,陈萍,侯晓娜.中国城市成人社区获得性肺炎665例病原学多中心调查[J].中华结核和呼吸杂志,2006,29(1):3-8. 被引量:788
  • 3黄大明,梁勇,农乐关.ICU痰革兰阴性杆菌菌群变迁及抗生素敏感性分析[J].华夏医学,2007,20(4):672-674. 被引量:2
  • 4Lim WS,van der Eerden MM,Lang R,et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study [J]. Thorax, 2003,58(5) : 377-382.
  • 5Marrie TJ, Poulin-Cosetello M, Beecroft MD, et al. Etiology of community-acquired pneumonia treated in an ambulatory setting[J]. Respir Med,2005,99(1):60-65.
  • 6Almirall J, Boixeda R, Bolibar I, et al. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study[J]. Respir Med, 2007,101(10) : 2168- 2175.
  • 7Thibodeau KP, Viera AJ. Atypical pathogens and challenges in community-acquired pneumonia[J]. Am Faro Physician, 2004, 69(7) : 1699-1706.
  • 8Saito A, Kohno S, Matsushima T, et ak Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan[J].J Infect Chemother, 2006,12 (2) : 63-69.
  • 9de Roux A, Ewig S, Garcia E, et al. Mixed community-acquired pneumonia in hospitalised patients [J]. Eur Respir J, 2006,27 (4) : 795-800.
  • 10Visnegarwala F, Lyer NG, Hamill RJ. Ventilator-associated pneumonia[J].Int J Antirnicrob Agents, 1998, 10(3): 191- 205.

共引文献208

同被引文献46

  • 1张建旺,贾晓琴,刘学军.肠球菌肺炎一例[J].中国药物与临床,2013,13(S1):143-144. 被引量:1
  • 2韩曙光.常用脱机模式的舒适度比较[J].齐齐哈尔医学院学报,2005,26(4):380-381. 被引量:8
  • 3Barros K V,Cassulino A P,Schalch L,et al.Supplemental intravenous n-3 fatty acids and n-3 fatty acid status and outcome in critically ill elderly patients in the ICU receiving enteral nutrition[J].Clinical Nutrition,2013,32(4):599.
  • 4Nordmann P,Cuzon G,Naas T.The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria[J].Lancet Infect Dis,2009,9(4):228-236.
  • 5Lockhart SR,Abramson MA,Beekmann SE.et al.Antimicrobial resistance among Gram-negative bacilli causing infections in intensive care unit patients in the United States between1993and 2004[J].J Clin Microbiol,2007,45(10):3352-3359.
  • 6Clinical and Laboratory Standards Institute.Performance standards for antimicrobial susceptibility testing[S].TwentyFirst Informational Supplement,2011:M100-S21.
  • 7Girometti N,Lewis RE,Giannella M,et al.Klebsiella pneumonia bloodstream infection:epidemiology and impact of inappropriate empirical therapy[J].Medicine(Baltimore),2014,93(17):298-309.
  • 8Szilágyi E,Füzi M,Brcz K,et al.Risk factors and outcomes for bloodstream infections with extended-spectrum betalactamase-producing Klebsiella pneumoniae;findings of the nosocomialsurveillance system in Hungary[J].Acta Microbiol Immunol Hung,2009,56(3):251-262.
  • 9Markogiannakis A,Tzouvelekis LS,Psichogiou M,et al.Confronting carbapenemase-producing Klebsiella pneumoniae[J].Future Microbiol,2013,8(9):1147-1161.
  • 10Henderson KL,Müller-Pebody B,Johnson AP,et al.Community-acquired,healthcare-associated and hospitalacquired bloodstream infection definitions in children:a systematic review demonstrating inconsistent criteria[J].J Hosp Infect,2013,85(2):94-105.

引证文献4

二级引证文献37

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部